Is to determinate the personalised factors that predict poor health status after specific oncological treatments
Big Data and Artificial Intelligence techniques will be used to integrate all available patient´s information with publicly available relevant biomedical databases as well as information from wearable devices used after the treatment.
CLARIFY proposes to integrate and analyse large volumes of heterogenous multivariate data to facilitate early discovery of risk factors that may deteriorate a patient condition after the end of oncological treatment. This will effectively help to stratify cancer survivors by risk in order to personalize their follow-up by better assessment of their needs
To predict patient-specific risk of developing secondary effects and toxicities of their cancer treatments, we will build novel models based on statistical relational learning and explainable AI techniques on top of the integrated knowledge graphs. The models will utilise background knowledge of the associated cancer biology and thus will help clinicians to make evidence-based post-treatment decisions in a way that is not possible at all with any existing approach
It was estimated that there were approximately 8.7 million cancer survivors in Europe. Survival rates of cancer patients were rather poor until recent decades, when diagnostic techniques have been improved and novel therapeutic options have been developed. It is estimated that more than 50% of adult patients diagnosed with cancer live at least 5 years in the US and Europe.
Many cancer survivors have unmet needs, especially when it comes to improving the quality of life, in addition to extending the duration of life. At least one quarter of cancer survivors report long-term poor health and disability . Some cancer survivors have levels of fatigue that are three-fold greater than the general population, and many carry a life-long fear of cancer recurrence.
Returning to work is also difficult for many cancer survivors, with one recent global survey reporting that more than one-third of employers described concerns about workplace discrimination against cancer survivors.